GenSight Biologics S.A.
GSGTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $48 | -$228 | $1,728 | -$283 |
| % Growth | 121.1% | -113.2% | 710.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $2,652 |
| Gross Profit | $48 | -$228 | $1,728 | -$2,404 |
| % Margin | 100% | 100% | 100% | 849.5% |
| R&D Expenses | $5,023 | $6,080 | $6,288 | $7,370 |
| G&A Expenses | $2,326 | $1,000 | $2,583 | $2,365 |
| SG&A Expenses | $2,553 | $768 | $2,843 | $5,480 |
| Sales & Mktg Exp. | $227 | -$232 | $260 | $3,115 |
| Other Operating Expenses | -$738 | $1,334 | $0 | $1 |
| Operating Expenses | $6,838 | $8,182 | $9,131 | $12,851 |
| Operating Income | -$8,313 | -$8,410 | -$7,403 | -$12,602 |
| % Margin | -17,318.9% | 3,688.6% | -428.4% | 4,453% |
| Other Income/Exp. Net | -$220 | $272 | $1,560 | -$1,657 |
| Pre-Tax Income | -$8,533 | -$8,138 | -$5,843 | -$14,260 |
| Tax Expense | -$325 | $16 | $5 | -$532 |
| Net Income | -$6,967 | -$8,153 | -$5,848 | -$14,258 |
| % Margin | -14,514.6% | 3,575.9% | -338.4% | 5,038.2% |
| EPS | -0.054 | -0.099 | -0.071 | -0.28 |
| % Growth | 45.4% | -40.8% | 74.8% | – |
| EPS Diluted | -0.054 | -0.099 | -0.071 | -0.28 |
| Weighted Avg Shares Out | 128,273 | 82,751 | 82,751 | 50,559 |
| Weighted Avg Shares Out Dil | 128,272 | 82,749 | 82,749 | 50,559 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2,554 | $621 | $932 | $1,810 |
| Depreciation & Amortization | $118 | $998 | $61 | $1,097 |
| EBITDA | -$5,862 | -$4,027 | -$7,342 | -$11,505 |
| % Margin | -12,211.8% | 1,766.2% | -424.9% | 4,065.4% |